Global Pigmentation Disorders Treatment Market, By Disease Type (Melasma, Vitiligo, Albinism, Post-Inflammatory Hyperpigmentation, and Others), Treatment Type (Pharmacological Treatment, Non-invasive Treatment, and Surgery), Drugs (Calcineurin Inhibitors, Melanocyte-Stimulating Hormone, and Other), Route of Administration (Oral, Topical, and Others), End-Users (Dermatology Clinics, Aesthetic Clinics, Homecare, Hospitals, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) - Industry Trends and Forecast to 2030.
Pigmentation Disorders Treatment Market Analysis and Size:
The increasing prevalence of pigmentation disorders across the globe is one of the major factors driving the growth of the treatment market for pigmentation disorders. The growing awareness and patient education, increasing disposable income, and healthcare expenditure accelerates the pigmentation disorders treatment market growth.
Data Bridge Market Research analyses that the global pigmentation disorders treatment market, which was USD 6,560.60 million in 2022, would rocket up to USD 12,369.18 million by 2030 and is expected to undergo a CAGR of 7.30 % during the forecast period. The melasma segment dominates the disease type segment of the pigmentation disorders treatment market owing to the advancements in technology that have led to the development of advancements in drugs for various use. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Pigmentation Disorders Treatment Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable 2015-2020) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
By Disease Type (Melasma, Vitiligo, Albinism, Post-Inflammatory Hyperpigmentation, and Others), Treatment Type (Pharmacological Treatment, Non-invasive Treatment, and Surgery), Drugs (Calcineurin Inhibitors, Melanocyte-Stimulating Hormone, and Other), Route of Administration (Oral, Topical, and Others), End-Users (Dermatology Clinics, Aesthetic Clinics, Homecare, Hospitals, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) |
|
Countries Covered |
U.S., Canada, Mexico, Brazil, Argentina, Peru, rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, rest of Middle East and Africa |
|
Market Players Covered |
Zerigo Health.(U.S.), Bausch Health Companies Inc. (U.S.),, Glenmark Pharmaceuticals Limited (India), Novartis AG (U.S.), Pfizer Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (U.S.), Dr. Reddy’s Laboratories Ltd. (India), Mylan N.V. (U.S.), Bayer AG (U.S.), CLINUVEL PHARMACEUTICALS LTD (Australia), Incyte (U.S.), Strides Pharma Science Limited (India), Panacea Biotec Ltd (U.S.), Belcher Pharmaceuticals, LLC (U.S.), LEO Pharma A/S (Germany), Astellas Pharma Inc. (U.S.), Episciences(U.S.), and Obagi Cosmeceuticals LLC (U.S.) |
|
Market Opportunities |
|
Market Definition
The global pigmentation disorders treatment market refers to the market for various products and therapies used to treat pigmentation disorders, which are conditions that affect the color of the skin, hair, or eyes. Pigmentation disorders can manifest as hypo-pigmentation (loss of skin color) or hyper-pigmentation (excessive skin color).
These disorders can be caused by various factors such as genetic mutations, hormonal changes, exposure to sunlight, skin injuries, or certain medical conditions. Some common pigmentation disorders include vitiligo, melasma, albinism, and post-inflammatory hyperpigmentation.
Global Pigmentation Disorders Treatment Market Dynamics
Drivers
- Increasing Prevalence of Pigmentation Disorders:
The rising prevalence of pigmentation disorders, such as melasma, vitiligo, and post-inflammatory hyperpigmentation, is a significant driver for the market. Factors such as sun exposure, hormonal changes, and genetic predisposition contribute to the growing incidence of these disorders, creating a demand for effective treatment options.
- Technological Advancements:
Advancements in treatment modalities, such as laser therapies, chemical peels, and cryosurgery, have significantly improved the outcomes of pigmentation disorders treatment. These technological advancements have led to the development of more precise, efficient, and less invasive procedures, driving market growth.
- Increasing Awareness and Cosmetic Concerns:
Growing awareness about the availability of various treatment options for pigmentation disorders has contributed to an increased demand for these treatments. Additionally, the rising emphasis on physical appearance and aesthetic concerns among the population has led to a surge in demand for pigmentation correction procedures, further driving the market growth.
Opportunities
- Rising Disposable Income and Affordability:
Increasing disposable income and affordability among individuals in developing economies have made pigmentation disorder treatments more accessible. As a result, a larger proportion of the population can afford these treatments, expanding the market.
- Growing Geriatric Population:
The global geriatric population is rising, and pigmentation disorders are more prevalent among older individuals. Age-related pigmentation disorders, such as senile and solar lentigines, are becoming increasingly common. This demographic trend contributes to the market's growth as the demand for effective treatment options for pigmentation disorders increases.
Challenges/ Restraints
- High Treatment Costs:
The cost of pigmentation disorders treatment can be high, especially for advanced therapies such as laser treatments or cosmetic procedures. Affordability issues can limit access to these treatments, particularly in developing countries with limited healthcare resources.
- Side Effects and Risks:
Some pigmentation disorders treatment options, such as chemical peels or laser therapy, may carry potential risks and side effects. Concerns about adverse reactions or complications may deter individuals from seeking or continuing treatment.
This global pigmentation disorders treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Global Pigmentation Disorders Treatment Market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In June 2023, Merck, known as MSD outside of the United States and Canada, announced the completion of the acquisition of the Prometheus Biosciences, Inc. (“Prometheus”). Prometheus is now a wholly-owned subsidiary of Merck, and the common stock of Prometheus will no longer be listed or traded on the Nasdaq global market
- In May 2023, Sandoz, a global leader in off-patent (generic and biosimilar) medicines, announced a multi-year partnership with Just - Evotec Biologics, the Seattle-based subsidiary of Evotec SE.
Global Pigmentation Disorders Treatment Market scope
The global pigmentation disorders treatment market is segmented on the basis of disease type, treatment type, drugs, route of administration, end users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
By disease type
- Melasma
- Vitiligo
- Albinism
- Post-Inflammatory Hyperpigmentation
- Others
By treatment type
- Pharmacological Treatment
- Non-invasive Treatment
- Surgery
By drugs
- Calcineurin Inhibitors
- Melanocyte-Stimulating Hormone
- Other
By Route of administration
- Oral
- Topical
- Others
By end users
- Dermatology Clinics
- Aesthetic Clinics
- Homecare
- Hospitals
- Others
By Distribution channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Global Pigmentation Disorders Treatment Market regional analysis/insights
The global pigmentation disorders treatment market is analysed and market size insights and trends are provided for country, disease type, treatment type, drugs, route of administration, end users and distribution channel as referenced above.
The countries covered in the global pigmentation disorders treatment market report are U.S., Canada, Mexico, Brazil, Argentina, Peru, rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, rest of Middle East and Africa.
North America dominates the pigmentation disorders treatment market due to major key players, high disposable income, high healthcare expenditure, and well-developed healthcare sector in this region. Asia-Pacific is expected to grow during the forecast period of 2023-2030 due to the increasing research and development activities, rising investment in the healthcare sector, and growing government support.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global pigmentation disorders treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Global Pigmentation Disorders Treatment Market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Global Pigmentation Disorders Treatment Market. The data is available for historic period 2010-2020.
Competitive Landscape and Global Pigmentation Disorders Treatment Market share Analysis
The global pigmentation disorders treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Global Pigmentation Disorders Treatment Market.
Some of the major players operating in the market are:
- Zerigo Health.(U.S.)
- Bausch Health Companies Inc. (U.S.)
- Glenmark Pharmaceuticals Limited (India)
- Novartis AG (U.S.)
- Pfizer Inc. (U.S.)
- Teva Pharmaceutical Industries Ltd. (U.S.)
- Dr. Reddy’s Laboratories Ltd. (India)
- Mylan N.V. (U.S.)
- Bayer AG (U.S.)
- CLINUVEL PHARMACEUTICALS LTD (Australia)
- Incyte (U.S.)
- Strides Pharma Science Limited (India)
- Panacea Biotec Ltd (U.S.)
- Belcher Pharmaceuticals, LLC (U.S.)
- LEO Pharma A/S (Germany)
- Astellas Pharma Inc. (U.S.)
- Episciences(U.S.)
- Obagi Cosmeceuticals LLC (U.S.)
SKU-
